COMMUNIQUÉS West-GlobeNewswire

Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
16/04/2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex virus infections, with [...]
Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND
16/04/2026
Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a first‑in‑class, mutation‑ [...]
Roquette réalise avec succès son émission obligataire hybride, pour un montant de 600 millions d'euros
16/04/2026
Roquette réalise avec succès son émission obligataire hybride, pour un montant de 600 millions d'euros Lille, le 16 avril 2026 - Roquette, un leader mondial des ingrédients d'origine végétale et un fournisseur majeur d’ [...]
Eurobio Scientific signe un accord définitif en vue de l'acquisition de la division « Lab Products » de CareDx dédiée à la transplantation
16/04/2026
EUROBIO SCIENTIFIC SIGNE UN ACCORD DÉFINITIF EN VUE DE L'ACQUISITION DE LA DIVISION « LAB PRODUCTS 1 » DE CAREDX DÉDIÉE À LA TRANSPLANTATION L'acquisition du portefeuille « Lab Products » de CareDx ouvre de nouvelles [...]
TME PHARMA ANNONCE LA PUBLICATION DANS *NATURE COMMUNICATIONS* DES RÉSULTATS DE L'ESSAI GLORIA CONCERNANT LE VOLET D'EXTENSION A DE PHASE 1/2 DE LA « TRIPLE THÉRAPIE » NOX-A12
16/04/2026
TME PHARMA ANNONCE LA PUBLICATION DANS *NATURE COMMUNICATIONS* DES RÉSULTATS DE L'ESSAI GLORIA CONCERNANT LE VOLET D'EXTENSION A DE PHASE 1/2 DE LA « TRIPLE THÉRAPIE » NOX-A12 Berlin, Allemagne, le 16 avril 2026, 8 h 00 [...]
ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase
16/04/2026
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]
Pharming Group announces the 2026 Annual General Meeting of Shareholders
16/04/2026
Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “ [...]
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
16/04/2026
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) -- BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or [...]
Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine
16/04/2026
COPENHAGEN, Denmark, April 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA ® (recombinant, adsorbed) for active immunization [...]
Eurobio scientific signs definitive agreement to acquire CareDx’s transplant Lab Product division
16/04/2026
EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx’s ‘lab products’ portfolio creates new opportunities for growth and innovation in the fast growing [...]
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications
16/04/2026
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany , April 16, 2026, 08.00am CET – TME Pharma N.V. (Euronext Growth [...]
Greywolf Therapeutics appoints Edwin Moses as Chair
16/04/2026
OXFORD, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, has appointed Edwin [...]
UroFlow Claims Evaluated: Reviewing the Official Website Benefits & Ingredients to Support Prostate Health
16/04/2026
A 2026 consumer information overview of how UroFlow presents its Saw Palmetto, Pygeum Africanum, Lycopene, and Tomato Sauce Trick ingredient references, official website benefit descriptions, pricing structure, and [...]
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
15/04/2026
WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
Running with Purpose: Nashville Podiatrist Dr. Lanier Shares Expert Tips for Injury-Free Half Marathon Training
15/04/2026
NASHVILLE, Tenn., April 15, 2026 (GLOBE NEWSWIRE) -- Dr. Yerusalem Lanier is preparing to take on the Rock ‘n’ Roll Half Marathon on April 25, 2026, for the second year alongside her daughters and husband. For Dr. [...]
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
15/04/2026
Expanded treatment in community settings will reduce patient burden Option to redose patients granted in both Ntrust-1 and Ntrust-2 studies Rheumatoid arthritis cohort to be added to Ntrust-2 Dosing continues at 4 [...]
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
15/04/2026
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter [...]
Algernon Health Announces Effective Date of Previously Announced Name Change to “Grey Matters Health Inc.” and its 10:1 Share Consolidation
15/04/2026
VANCOUVER, British Columbia, April 15, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “ Company ” or “ Algernon ”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces that effective [...]
Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection
15/04/2026
- Turletricin Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA - - Elion to Present Turletricin Clinical Data at ESCMID Global - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Elion [...]

Pages